Stock data
Immunovant, Inc. (IMVT)
Immunovant, Inc. (IMVT) reported net income of -US$505.61M for fiscal 2026. The figures below come from the company's SEC filings.
Annual results
Data as of 2026-03-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2026 | — | — | — | -US$505.61M | — |
| 2025 | — | — | — | -US$413.84M | — |
| 2024 | — | — | — | -US$259.34M | — |
| 2023 | — | — | — | -US$210.96M | — |
| 2022 | — | — | — | -US$156.73M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$153.22M | — |
| 2026-03-31 | — | -US$147.86M | — |
| 2025-12-31 | — | -US$110.64M | — |
| 2025-09-30 | — | -US$126.50M | — |
| 2025-06-30 | — | -US$120.61M | — |
| 2025-03-31 | — | -US$106.45M | — |
| 2024-12-31 | — | -US$111.12M | — |
| 2024-09-30 | — | -US$109.12M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.